Details of the Drug Combination

General Information of Drug Combination (ID: DC9S8XC)

Drug Combination Name
Enzalutamide Flutamide
Indication
Disease Entry Status REF
Prostate Cancer Phase 4 [1]
Component Drugs Enzalutamide   DMGL19D Flutamide   DMK0O7U
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Enzalutamide
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
Enzalutamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Enzalutamide Interacts with 117 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Response To Substance [7]
Very long chain fatty acid elongase 7 (ELOVL7) OT89NYVC ELOV7_HUMAN Decreases Expression [4]
Bone morphogenetic protein receptor type-1B (BMPR1B) OTGFN0OD BMR1B_HUMAN Decreases Expression [4]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) OTKOZRZP PLOD2_HUMAN Decreases Expression [4]
RNA polymerase II elongation factor ELL2 (ELL2) OTZJRTFM ELL2_HUMAN Decreases Expression [4]
Suppressor of cytokine signaling 2 (SOCS2) OTBPNKJQ SOCS2_HUMAN Decreases Expression [4]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Decreases Expression [4]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Decreases Expression [4]
Unconventional myosin-Ib (MYO1B) OTGZUJ0I MYO1B_HUMAN Decreases Expression [4]
Kinesin heavy chain isoform 5C (KIF5C) OT35570Y KIF5C_HUMAN Decreases Expression [4]
Transcription factor Maf (MAF) OT1GR3IZ MAF_HUMAN Decreases Expression [4]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Decreases Expression [4]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Expression [4]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Expression [4]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [4]
Microtubule-associated protein 2 (MAP2) OT6UYT3X MTAP2_HUMAN Decreases Expression [4]
Plastin-2 (LCP1) OTK61F2A PLSL_HUMAN Decreases Expression [4]
Kallikrein-2 (KLK2) OT9RE37R KLK2_HUMAN Decreases Expression [4]
Zinc-alpha-2-glycoprotein (AZGP1) OTPD9TDR ZA2G_HUMAN Decreases Expression [4]
Dipeptidyl peptidase 4 (DPP4) OT16MVL9 DPP4_HUMAN Decreases Expression [4]
Prostaglandin E2 receptor EP4 subtype (PTGER4) OT2GBV06 PE2R4_HUMAN Decreases Expression [4]
Phospholipase A2 group V (PLA2G5) OTQRSKCZ PA2G5_HUMAN Decreases Expression [4]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Decreases Expression [4]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Decreases Expression [4]
Selenoprotein P (SELENOP) OT02B8IR SEPP1_HUMAN Decreases Expression [4]
AF4/FMR2 family member 3 (AFF3) OTR0705Z AFF3_HUMAN Decreases Expression [4]
Cysteine-rich secretory protein 3 (CRISP3) OTBSWMPL CRIS3_HUMAN Decreases Expression [4]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [4]
Testican-1 (SPOCK1) OTLTDGK7 TICN1_HUMAN Decreases Expression [4]
Acyl-coenzyme A synthetase ACSM1, mitochondrial (ACSM1) OT1TS9M9 ACSM1_HUMAN Decreases Expression [4]
Ras GTPase-activating-like protein IQGAP2 (IQGAP2) OTX2UA7P IQGA2_HUMAN Decreases Expression [4]
Glycine N-methyltransferase (GNMT) OT0O2OQO GNMT_HUMAN Decreases Expression [4]
Ketimine reductase mu-crystallin (CRYM) OTRGSR6B CRYM_HUMAN Decreases Expression [4]
Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase (ADPRM) OTXE3X5J ADPRM_HUMAN Decreases Expression [4]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Decreases Expression [4]
EF-hand calcium-binding domain-containing protein 12 (EFCAB12) OT1QZJEI EFC12_HUMAN Decreases Expression [4]
Rho-related GTP-binding protein RhoU (RHOU) OTERIAD4 RHOU_HUMAN Decreases Expression [4]
Transient receptor potential cation channel subfamily M member 8 (TRPM8) OT7ACGYK TRPM8_HUMAN Decreases Expression [4]
Alpha-protein kinase 2 (ALPK2) OTWZZDQ9 ALPK2_HUMAN Decreases Expression [4]
Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial (AADAT) OTO68C3Y AADAT_HUMAN Decreases Expression [4]
Chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1) OTBML9D9 CGAT1_HUMAN Decreases Expression [4]
Homeobox protein Nkx-3.1 (NKX3-1) OT0DO6ZU NKX31_HUMAN Decreases Expression [4]
Specifically androgen-regulated gene protein (C1ORF116) OTPYEXDM SARG_HUMAN Decreases Expression [4]
ER degradation-enhancing alpha-mannosidase-like protein 3 (EDEM3) OT4GJX9R EDEM3_HUMAN Decreases Expression [4]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1) OT3JQD99 SIA7A_HUMAN Decreases Expression [4]
Teneurin-1 (TENM1) OTSKSU4V TEN1_HUMAN Decreases Expression [4]
Transmembrane and coiled-coil domain protein 3 (TMCC3) OTAIQ6V6 TMCC3_HUMAN Decreases Expression [4]
E3 ubiquitin-protein ligase NEURL1B (NEURL1B) OT3BZWO8 NEU1B_HUMAN Affects Expression [5]
Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) OTOKUXUH ADA10_HUMAN Affects Expression [5]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Expression [5]
Sushi domain-containing protein 5 (SUSD5) OTIMJGDH SUSD5_HUMAN Affects Expression [5]
GDP-mannose 4,6 dehydratase (GMDS) OTWV79YD GMDS_HUMAN Affects Expression [5]
Polycomb protein EED (EED) OTJFHCDF EED_HUMAN Decreases Expression [8]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [9]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Affects Expression [5]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [9]
Beta-microseminoprotein (MSMB) OTYORAJC MSMB_HUMAN Decreases Expression [10]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Affects Expression [5]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Affects Expression [5]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Decreases Cleavage [9]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [8]
Membrane cofactor protein (CD46) OTQ8NWJD MCP_HUMAN Increases Expression [11]
Aspartate aminotransferase, cytoplasmic (GOT1) OTZLM5UB AATC_HUMAN Affects Expression [5]
Midkine (MDK) OTF24HKC MK_HUMAN Affects Expression [5]
Hepatocyte nuclear factor 1-beta (HNF1B) OTSYIC3T HNF1B_HUMAN Affects Expression [5]
Small ribosomal subunit protein eS19 (RPS19) OTBKGP48 RS19_HUMAN Affects Expression [5]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [8]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Affects Expression [5]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Affects Expression [5]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Affects Expression [5]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Affects Expression [5]
Presenilin-1 (PSEN1) OTKL39RT PSN1_HUMAN Affects Expression [5]
Presenilin-2 (PSEN2) OTOW778B PSN2_HUMAN Affects Expression [5]
Hepatocyte nuclear factor 3-alpha (FOXA1) OTEBY0TD FOXA1_HUMAN Affects Expression [5]
Ubiquitin-ribosomal protein eS31 fusion protein (RPS27A) OTIIGGZ2 RS27A_HUMAN Affects Expression [5]
Protein jagged-1 (JAG1) OT3LGT6K JAG1_HUMAN Affects Expression [5]
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) OTTM6KRB ADA17_HUMAN Affects Expression [5]
Neurogenic locus notch homolog protein 2 (NOTCH2) OTQ3Y9PA NOTC2_HUMAN Affects Expression [5]
Recombining binding protein suppressor of hairless (RBPJ) OTD7CUG0 SUH_HUMAN Affects Expression [5]
Histone acetyltransferase p300 (EP300) OTL8QJDX EP300_HUMAN Affects Expression [5]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5) OT404F9K FKBP5_HUMAN Decreases Expression [9]
SNW domain-containing protein 1 (SNW1) OTKWG3PS SNW1_HUMAN Affects Expression [5]
Transcription factor HES-1 (HES1) OT8P19W2 HES1_HUMAN Affects Expression [5]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Decreases Expression [8]
Polycomb protein SUZ12 (SUZ12) OT655XF8 SUZ12_HUMAN Decreases Expression [8]
Histone-lysine N-methyltransferase EZH2 (EZH2) OTIEHTKW EZH2_HUMAN Decreases Expression [8]
Probable E3 ubiquitin-protein ligase DTX2 (DTX2) OT7QLDU4 DTX2_HUMAN Affects Expression [5]
E3 ubiquitin-protein ligase MIB1 (MIB1) OT5C404P MIB1_HUMAN Affects Expression [5]
NF-kappa-B-activating protein (NKAP) OT7K7I8Q NKAP_HUMAN Affects Expression [5]
Probable E3 ubiquitin-protein ligase DTX3 (DTX3) OTSUUV9N DTX3_HUMAN Affects Expression [5]
Polypeptide N-acetylgalactosaminyltransferase 11 (GALNT11) OTANT9E6 GLT11_HUMAN Affects Expression [5]
Gamma-secretase subunit APH-1B (APH1B) OTQHPTGC APH1B_HUMAN Affects Expression [5]
Nicastrin (NCSTN) OT5QBTA4 NICA_HUMAN Affects Expression [5]
Mastermind-like protein 1 (MAML1) OTQA4DDN MAML1_HUMAN Affects Expression [5]
CREB-binding protein (CREBBP) OTPA4QGM CBP_HUMAN Affects Expression [5]
Histone acetyltransferase KAT2B (KAT2B) OTWQITWK KAT2B_HUMAN Affects Expression [5]
E3 ubiquitin-protein ligase MIB2 (MIB2) OTJCC3HS MIB2_HUMAN Affects Expression [5]
Gamma-secretase subunit APH-1A (APH1A) OT97F1TU APH1A_HUMAN Affects Expression [5]
p53 apoptosis effector related to PMP-22 (PERP) OTP0YL53 PERP_HUMAN Affects Expression [5]
E3 ubiquitin-protein ligase Itchy homolog (ITCH) OTUOMKF5 ITCH_HUMAN Affects Expression [5]
Mastermind-like protein 3 (MAML3) OTZFV53Z MAML3_HUMAN Affects Expression [5]
Intraflagellar transport protein 74 homolog (IFT74) OTZBFEDD IFT74_HUMAN Affects Expression [5]
RNA-binding protein 15 (RBM15) OT8ZPGWF RBM15_HUMAN Affects Expression [5]
Msx2-interacting protein (SPEN) OT37A2MD MINT_HUMAN Affects Expression [5]
Sphingosine 1-phosphate receptor 3 (S1PR3) OTXBIYO8 S1PR3_HUMAN Affects Expression [5]
GDP-fucose protein O-fucosyltransferase 1 (POFUT1) OTOBJZIT OFUT1_HUMAN Affects Expression [5]
Notchless protein homolog 1 (NLE1) OT1BV82K NLE1_HUMAN Affects Expression [5]
Gamma-secretase subunit PEN-2 (PSENEN) OTJ7M7G9 PEN2_HUMAN Affects Expression [5]
Protein sel-1 homolog 1 (SEL1L) OTC0FB7T SE1L1_HUMAN Affects Expression [5]
Intraflagellar transport protein 172 homolog (IFT172) OT12DW08 IF172_HUMAN Affects Expression [5]
Neurogenic locus notch homolog protein 3 (NOTCH3) OTMVVA7F NOTC3_HUMAN Affects Expression [5]
Protein jagged-2 (JAG2) OTH7KRRF JAG2_HUMAN Affects Expression [5]
E3 ubiquitin-protein ligase DTX4 (DTX4) OTGX30AO DTX4_HUMAN Affects Expression [5]
Epsin-1 (EPN1) OT4Q1NIV EPN1_HUMAN Affects Expression [5]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Response To Substance [12]
Ephrin type-B receptor 4 (EPHB4) OTKLPVXJ EPHB4_HUMAN Affects Response To Substance [9]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Response To Substance [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 117 DOT(s)
Indication(s) of Flutamide
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [3]
Flutamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Antagonist [13]
------------------------------------------------------------------------------------
Flutamide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Flutamide Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [16]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [15]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [15]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Metabolism [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Flutamide Interacts with 35 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Activity [18]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [19]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [20]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Response To Substance [21]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Response To Substance [21]
3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2) OTTG0NFD S5A2_HUMAN Decreases Activity [22]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [23]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Increases Expression [24]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [25]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [26]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [27]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [28]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [24]
Protein S100-A8 (S100A8) OTVMOB3F S10A8_HUMAN Increases Expression [27]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [27]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [26]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Expression [24]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [24]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Decreases Expression [29]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Decreases Secretion [30]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Activity [31]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Increases Expression [24]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Affects Localization [32]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [24]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Increases Expression [24]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [24]
Advanced glycosylation end product-specific receptor (AGER) OTPY0IH7 RAGE_HUMAN Increases Expression [27]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Increases Expression [24]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Expression [28]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Increases Expression [27]
Homeobox protein Nkx-3.1 (NKX3-1) OT0DO6ZU NKX31_HUMAN Decreases Expression [33]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [25]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [24]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Response To Substance [34]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Increases Hydrolysis [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 DOT(s)

References

1 ClinicalTrials.gov (NCT02918968) Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6943).
4 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
5 NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
8 Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol Appl Pharmacol. 2020 Oct 1;404:115200. doi: 10.1016/j.taap.2020.115200. Epub 2020 Aug 14.
9 Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance. J Biol Chem. 2020 Apr 17;295(16):5470-5483. doi: 10.1074/jbc.RA119.011385. Epub 2020 Mar 17.
10 In silico and in vitro assessment of androgen receptor antagonists. Comput Biol Chem. 2021 Jun;92:107490. doi: 10.1016/j.compbiolchem.2021.107490. Epub 2021 Apr 23.
11 Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
12 Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.
13 Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
14 The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
15 Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
16 Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
17 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
18 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
19 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
20 Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43.
21 Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.
22 Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. Toxicol In Vitro. 2007 Apr;21(3):502-8.
23 Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters. Environ Int. 2015 Jan;74:60-70.
24 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
25 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
26 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
27 Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
28 Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. J Med Chem. 2011 Jan 13;54(1):302-11. doi: 10.1021/jm101163m. Epub 2010 Dec 3.
29 Role of connexin 43 in cadmium-induced proliferation of human prostate epithelial cells. J Appl Toxicol. 2017 Aug;37(8):933-942. doi: 10.1002/jat.3441. Epub 2017 Feb 8.
30 DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
31 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
32 Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25.
33 Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin. 2007 Mar;28(3):423-30. doi: 10.1111/j.1745-7254.2007.00501.x.
34 Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab Dispos. 2011 Aug;39(8):1388-95. doi: 10.1124/dmd.110.037077. Epub 2011 May 3.
35 Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2012 Apr;40(4):671-9. doi: 10.1124/dmd.111.043067. Epub 2011 Dec 29.